Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTIA-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Hormonal contraceptive (off-label: menstrual regulation, acne, hirsutism)
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol undergoes first-pass metabolism in liver and gut via CYP3A4; levonorgestrel metabolized via CYP3A4 and reduction/sulfation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
98-99% bound, primarily to albumin and sex hormone-binding globulin (SHBG)
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
2.8-4.1 L/kg, indicating extensive tissue distribution and accumulation in fat and reproductive organs
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 60-80% (first-pass metabolism reduces systemic availability); IV: 100%
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No data available for fictional drug ALYACEN 777.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; no specific dose adjustment recommended.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, then 7 days placebo).
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women. No specific geriatric dosing recommendations; follow standard dosing if prescribed off-label, but consider increased risk of thromboembolism and cardiovascular events.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptives. Risk increases with age (especially >35) and number of cigarettes smoked. Women >35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders,Elevated blood pressure,Hepatic neoplasia or active liver disease,Gallbladder disease,Carbohydrate/lipid effects,Ocular changes (retinal thrombosis),Headache/migraine,Menstrual irregularities
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions are known. Grapefruit juice may increase estrogen levels but not clinically significant; no dietary restrictions required. Take with food or milk if nausea occurs.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and estrogen exposure. Second and third trimesters: Increased risk of fetal genital abnormalities, urogenital malformations, and potential long-term effects on reproductive development. Use only if pregnancy is ruled out.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in human milk. M/P ratio not established. May reduce milk production and composition. Potential for adverse effects in the nursing infant including jaundice, breast enlargement, and hormonal disruption. Use is contraindicated during breastfeeding.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No safe dose in pregnancy. Contraindicated and should be discontinued immediately if pregnancy occurs. No dose adjustment possible due to teratogenicity.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Portia-21 (oral contraceptive pill containing levonorgestrel and ethinyl estradiol) requires strict adherence to a daily schedule; missed pills increase ovulation risk. First dose should be taken on the first day of menstruation for immediate contraceptive effect. Counsel patients that breakthrough bleeding is common in initial cycles but usually resolves. Concomitant use with CYP3A4 inducers (e.g., rifampin, St. John's wort) reduces efficacy and requires alternative contraception. Monitor blood pressure and consider increased thrombotic risk in smokers over age 35.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill at the same time every day, even if you do not have sex that day.,If you miss a pill, refer to the package insert instructions; use backup contraception for 7 days if late by more than 12 hours.,Breakthrough spotting or nausea may occur initially but often improves; do not stop taking the pill.,Tell your doctor about all medications, including over-the-counter drugs and herbal supplements.,Smoking while taking this pill increases risk of blood clots, especially if over 35 years old.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTIA-21 vs ALYACEN 777, answered by our medical review team.
PORTIA-21 is a Oral Contraceptive that works by Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTIA-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTIA-21 is: One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTIA-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTIA-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and est. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.